Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Comparison Among Clomipramine, Fluoxetine, and Placebo for the Treatment of Anxiety Disorders in Children and Adolescents

Full text
Author(s):
Gouvea da Costa, Carolina Zadrozny [1] ; Campelo Borba de Morais, Rosa Magaly [1] ; Trevisan Zanetta, Dirce Maria [2] ; Turkiewicz, Gizela [3] ; Neto, Francisco Lotufo [1] ; Morikawa, Marcia [1] ; Rodrigues, Camila Luisi [1] ; Labbadia, Eunice Monteiro [1] ; Asbahr, Fernando Ramos [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Anxiety Disorders Children & Adolescent Program, Dept & Inst Psychiat, BR-05403010 Sao Paulo - Brazil
[2] Univ Sao Paulo, Sch Publ Hlth, BR-05403010 Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept & Inst Psychiat, Childhood & Adolescence Eating Disorder Teaching, BR-05403010 Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY; v. 23, n. 10, p. 687-692, DEC 1 2013.
Web of Science Citations: 8
Abstract

Objective: The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders. Method: Thirty subjects (ages 7-17 years), who were diagnosed with generalized anxiety disorder and/or separation anxiety disorder and/or social phobia, were submitted to a 12 week double-blind, randomized, placebo-controlled trial of clomipramine and fluoxetine. The instruments included: the Schedule for Affective Disorders and Schizophrenia, the Multidimensional Anxiety Scale for Children, the Children's Depression Inventory, the Clinical Global Impressions, and the Children's Global Assessment Scale. Results: All groups (clomipramine {[}n=9], fluoxetine {[}n=10], placebo {[}n=11]) showed a significant improvement after 12 weeks of treatment. There were significant differences between the fluoxetine and placebo groups in some ratings of anxiety severity and impairment. No significant differences were observed between clomipramine and placebo groups or between fluoxetine and clomipramine groups. Conclusions: Treatment with placebo showed an unusual high response rate. Clomipramine showed similar efficacy compared with fluoxetine, although it was not superior to placebo. (AU)